ArticleMaterials today. Bio2025
A matrix metalloproteinase-responsive hydrogel with spatially orchestrated delivery of stem cells and raleukin for enhanced bone regeneration.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Graphene oxide-induced multiple iPSC spheroid formation for enhanced production of angiogenic exosomes accelerating tissue regeneration.Materials today. Bio · 2026Article
- Hydrogel Implementing Drug Delivery in Cranial Bone Tissue Engineering.Journal of functional biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell therapy has demonstrated efficacy in treating bone defects. However, a critical challenge remains in effectively anchoring stem cells at the defect site and creating a conducive microenvironment that supports their proliferation and enhances bone regeneration. To address the dynamic microenvironmental changes occurring at different stages of bone defect healing, we designed a matrix metalloproteinase (MMP)-responsive biomimetic multilayer hydrogel system. The intermediate layer contains raleukin to provide targeted anti-inflammatory therapy, while the innermost layer comprises alginate/carboxymethyl cellulose microcapsules encapsulating bone marrow mesenchymal stem cells (BMSCs) to support stem cell retention, viability, and maintenance of stemness. The synergistic interaction between encapsulated BMSCs and raleukin effectively modulates the immune-inflammatory response and promotes angiogenesis, osteoblast proliferation, and differentiation. In vivo evaluation using rat skull defect model additionally demonstrates that the hydrogel system significantly enhances bone regeneration by accelerating bone metabolism and promoting osteoblast differentiation following implantation. Collectively, these findings underscore the therapeutic potential of MMP-responsive hydrogel platforms in advancing bone regeneration and related biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.